Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study.
Melissa Lynne JohnsonByoung Chul ChoAlexander LuftJorge Alatorre-AlexanderSarayut Lucien GeaterKonstantin LaktionovSang-We KimGrygorii UrsolMaen HusseinFarah Louise LimCheng-Ta YangLuiz Henrique AraujoHaruhiro SaitoNiels ReinmuthXiaojin ShiLynne PooleSolange PetersEdward B GaronTony S K Moknull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
D + CT significantly improved PFS versus CT. A limited course of tremelimumab added to durvalumab and chemotherapy significantly improved OS and PFS versus CT, without meaningful additional tolerability burden, representing a potential new option in first-line mNSCLC.